Doranidazole

Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors[1][2][3].

Product Specifications

CAS Number

[149838-23-3]

Product Name Alternative

PR 350; RP 343

UNSPSC

12352005

Target

Biochemical Assay Reagents

Related Pathways

Others

Field of Research

Cancer

Smiles

OC[C@H](O)[C@@H](CO)OCN1C([N+]([O-])=O)=NC=C1

Molecular Formula

C8H13N3O6

Molecular Weight

247.21

References & Citations

[1]Yahiro T, et al. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J Radiat Res. 2005 Sep;46 (3) :363-72.|[2]Mizuho Aoki, et al. Effect of a Hypoxic Cell Sensitizer Doranidazole on the Radiation-induced Apoptosis of Mouse L5178Y Lymphoma Cells, Journal of Radiation Research, Volume 43, Issue 2, June 2002, Pages 161–166.|[3]Shibamoto Y, et al. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol. 2000 Aug;56 (2) :265-70.